Liquid biopsy research

Discover our comprehensive solutions

Liquid biopsy applications enable clinical researchers to investigate tumour heterogeneity in ways not possible with formalin-fixed paraffin-embedded (FFPE) samples.

Order now Request more information

Oncomine cfDNA Next-generation Sequencing Assays

Oncomine cfDNA Assay workflow
  • Limit of detection down to 0.1% limit of detection of SNV hotspots and indels
  • Mean sensitivity 90% and specificity 98% demonstrated on engineered oncology controls
  • Sample tolerance—flexible input amounts as low as 1 ng, and tolerance of sample input variability to accommodate more of your samples
  • High-value content—including T790M, L858R, Exon 19 del, C797S and many more, the assays enable analysis of SNV hotspots and indels identified by OncoNetwork Consortia and clinical researchers around the world
  • Efficient workflow enabled by the Ion S5 System, from a single tube of blood to results in just 2 days
Assay Genes Selected SNV hot spot
Oncomine Lung cfDNA Assays EGFR, ALK, BRAF, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, TP53

>150 hotspots including: EGFR T790M,
C797S, L858R, Exon 19 del
KRAS: G12X, G13X, Q61X
ALK Exon 21-25, L1152R, C1156Y, F1174C, L1196M
PIK3CA: E545K, H1047R, E542K

Learn more on our solutions from scientist

Affiliate Prof. José Luis Costa from i3S/IPATIMUP, Porto

“The new Lung cfDNA assay is able to amplify more difficult samples and allowed us the detection of mutations like EGFR T790M down to 0.14% allelic fraction in the plasma of lung cancer sample “

“Implementation of a methodology for the detection of somatic alterations in lung cancer plasma samples”

View Interview


Luca Quagliata, MD, of University Hospital, Basel, Switzerland

“Quality of DNA that we get from liquid biopsy is usually different from what we get from tissue samples.”


Nicola Normanno, Chief of Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy

“Tumours are highly heterogeneous and single mutation tests does not provide you with the information that you need to follow the molecular evolution of the disease; techniques like NGS are essential to generate a comprehensive molecular portrait of the tumour. “


The Oncomine Lung cfDNA Assay is part of a complete research solution to detect lung tumour-derived DNA (ctDNA) in cfDNA.

Learn more about Oncomine Lung cfDNA Assay ›

Oncomine Lung cfDNA assays using Multiplex cfDNA Reference Standard Set (Horizon Discovery)

Sample EGFRE746_A75
0.1%HDX 0.06


0.06 0.10 0.22 0.17 0.15 0.10
1%HDX 0.72 1.07 0.75 0.74 1.14 1.15 1.15 2.29
5%HDX 4.52 4.86 6.32 3.97 6.34 6.11 6.94 5.29
100%WT 0


0 0 0 0 0 0

Webinar on lung cancer liquid biopsy research analysis

Dr. Bea Bellosillo, head of the Molecular Biology Laboratory from the Hospital del Mar, in Barcelona, Spain will discuss her research on EGFR mutation monitoring in peripheral blood of non-small cell lung cancer samples using digital PCR.

Watch webinar

Lean more on our cfDNA extraction easy and fast workflow based on MagMAX magnetic-bead technology

“MagMax method turned out to be a simpler and faster method to isolate cfDNA from plasma. Additionally the method is better for isolating cfDNA from contaminant high molecular weight genomic DNA. In combination with sequencing and digital PCR we had robust results testing EGFR mutations on lung samples.” —Prof. José Luis Costa, Ph.D. IPATIMUP, Porto, Portugal

Download the application note

A complete next-generation sequencing workflow for circulating cell-free DNA isolation and analysis

Download now

Download the protocol for the Applied BiosystemsTM MagMAXTM Cell‑Free DNA Isolation Kit


Download now

Are you interested on both CTC and cfDNA isolation?

The Ion Torrent™ LiquidBiopsy™ Platform** is part of a comprehensive, two-day workflow that enables genomic research reporting data on circulating tumour cells (CTCs) and cell-free DNA (cfDNA) from a single blood sample.

Watch this quick webinar

“Getting the most from blood samples: peripheral monitoring research”.


The OncoNetwork

The OncoNetwork is comprised of twelve-translational cancer research institutes with many years of experience in adopting the latest molecular techniques like next generation sequencing - for lung research. Thermo Fisher Scientific and OncoNetwork consortium agreed to work together for the development of cfDNA NGS panels.

  • Université Paris Descartes, Paris, France
  • ARUP- Institute for Clinical and Experimental Pathology, Utah, USA
  • Institut Gustave Roussy, Paris, France
  • Radboud University Nijmegen Medical Centre, The Netherlands
  • VIOLLIER AG, Basel, Switzerland
  • Centro Ricerche Oncologiche Mercogliano, Avellino, Italy
  • ARC-NET University of Verona, Italy
  • Warwick University Medical School, United Kingdom
  • Trinity College Dublin, Ireland
  • Queen’s University, Ontario Canada
  • IPATIMUP Medical Faculty of Porto, Portugal
  • Faculty of Medicine, Kinki University, Osaka, Japa

More about OncoNetwork ›